# ๐Ÿงฌ Autosomal Dominant Polycystic Kidney Disease ### โšก Emergency Recognition & Management 1 **Subarachnoid Hemorrhage:** Sudden severe headache, nuchal rigidity โ†’ Immediate CT/CTA 2 **Cyst Infection:** Fever + flank pain in ADPKD โ†’ Fluoroquinolones (ciprofloxacin/levofloxacin) 4-6 weeks duration 3 **Cyst Hemorrhage:** Acute severe flank pain + gross hematuria, stable hemoglobin โ†’ Conservative management 4 **Cyst Rupture:** Sudden severe pain followed by rapid improvement โ†’ Usually self-resolves 5 **Hypertensive Crisis:** BP \>180/120 + symptoms โ†’ Gradual reduction, avoid rapid drops ### ๐Ÿšจ Cyst Complications: Recognition & Management #### ๐Ÿฉธ Cyst Hemorrhage - **Presentation:** Acute severe flank pain + gross hematuria - **Key Feature:** Hemoglobin usually stable (bleeding into cyst) - **Management:** Conservative, usually self-limited - **Duration:** Hematuria resolves in days to weeks #### ๐Ÿฆ  Cyst Infection - **Presentation:** Fever, flank pain, and elevated WBC - **Best Antibiotics:** Fluoroquinolones (excellent cyst penetration) - **Alternatives:** Trimethoprim-sulfamethoxazole - **Duration:** 4-6 weeks treatment typically needed - **Avoid:** Beta-lactams, nitrofurantoin (poor penetration) #### ๐Ÿ’ฅ Cyst Rupture - **Presentation:** Sudden severe pain followed by rapid improvement - **Mechanism:** Pressure relief as cyst contents leak - **Hematuria:** May have brief episode - **Management:** Usually self-resolves without treatment ### ๐Ÿ“Š Clinical Significance - **Global Prevalence:** Up to 12 million people worldwide - **ESRD Cause:** 4th leading cause of end-stage renal disease - **Most Common:** Hereditary kidney disease globally - **Healthcare Burden:** Significant economic impact - **Variability:** Wide clinical spectrum from mild to severe - **Systemic Disease:** Multiple organ involvement ### ๐Ÿงฌ Genetic Basis - **PKD1 Gene:** 78% of cases, chromosome 16p13.3 - **PKD2 Gene:** 15% of cases, chromosome 4q21-23 - **Rare Genes:** IFT140, GANAB, ALG5, ALG9, NEK8, DNAJB11 - **PKD1 Severity:** More severe disease, earlier ESRD onset - **PKD2 Course:** Milder phenotype, later progression - **Protein Products:** Polycystin-1 and polycystin-2 ### ๐Ÿ” Diagnostic Criteria #### Ravine Criteria (Age-Dependent) - ๐Ÿ”น **15-29 years:** โ‰ฅ2 cysts (unilateral or bilateral) - ๐Ÿ”น **30-59 years:** โ‰ฅ2 cysts in each kidney - ๐Ÿ”น **โ‰ฅ60 years:** โ‰ฅ4 cysts in each kidney #### Pei Unified Criteria - โœ… **15-39 years:** โ‰ฅ3 cysts (100% PPV) - โŒ **\>40 years:** โ‰ค2 cysts excludes ADPKD (100% NPV) - ๐ŸŽฏ **Advantage:** Works for PKD1 and PKD2 ### ๐Ÿงฌ Genetic Testing Decision Aid Patient Age: Family History: Clinical Scenario: Genetic Testing Recommendation Genetic testing recommended Based on clinical scenario and family history ### ๐Ÿ“ˆ Mayo Imaging Classification (htTKV) - **Class 1A:** Estimated kidney growth \<1.5%/year (low risk) - **Class 1B:** Estimated kidney growth 1.5-3.0%/year (low-intermediate risk) - **Class 1C:** Estimated kidney growth 3.0-4.5%/year (intermediate-high risk) - **Class 1D:** Estimated kidney growth 4.5-6.0%/year (high risk) - **Class 1E:** Estimated kidney growth \>6.0%/year (highest risk) - **Method:** Uses age- and sex-adjusted htTKV growth trajectories from the Mayo Clinic PKD database ### โš–๏ธ Progression Risk Factors - **PKD1 Mutations:** More severe disease, average ESRD age 54 - **PKD2 Mutations:** Milder progression, average ESRD age 74 - **Early Hypertension:** Before age 35 indicates rapid progression - **Male Gender:** More rapid progression than females - **Height-Adjusted TKV:** Most important predictor of progression - **Family History:** Grandfather's transplant suggests moderate progression ### ๐Ÿ’Š Tolvaptan: First Disease-Modifying Therapy 1 **Patient Selection:** CKD stages 1-4 (eGFR โ‰ฅ25), evidence of rapid progression, adequate liver function 2 **Progression Evidence:** Declining eGFR, increasing TKV, or high-risk features (height-adjusted TKV \>600 mL/m) 3 **Critical Monitoring:** Monthly liver function tests for first 18 months (ALT \>3x ULN requires discontinuation) 4 **Safety Profile:** Idiosyncratic liver injury in 4.4% of patients - most important monitoring requirement 5 **Efficacy Monitoring:** Annual TKV by MRI, eGFR decline rate assessment ### ๐Ÿ“ Height-Adjusted TKV Calculator Total Kidney Volume (mL): 800 mL Height (cm): 170 cm Height-Adjusted TKV 277 mL/m Mayo Class 1A - Low risk Tolvaptan not indicated ### ๐Ÿง  Intracranial Aneurysm Screening #### โš ๏ธ CRITICAL: MRA vs MRI for Aneurysm Screening **MRA (Magnetic Resonance Angiography)** is the test of choice for intracranial aneurysm screening, NOT standard brain MRI. MRA specifically images blood vessels and can detect aneurysms โ‰ฅ3mm. Standard brain MRI does not adequately visualize cerebral vasculature. #### Epidemiology - **ADPKD Prevalence:** 8-10% (4x higher than general population) - **General Population:** 2-3% - **Family History:** Higher screening frequency needed - **High-Risk Features:** \>7mm, irregular shape, symptoms #### Screening Protocol - **Test of Choice:** MRA brain (not standard MRI) - **Initial:** Symptoms or high-risk occupation - **Repeat:** Every 5-10 years if negative - **Indications:** Headaches, family history, anxiety #### High-Priority Screening Candidates Family history of aneurysms or subarachnoid hemorrhage, high-risk occupations, patient anxiety, new headaches ### ๐Ÿซ€ Polycystic Liver Disease - **Prevalence:** 81.7% of ADPKD patients have hepatic cysts - **Age Correlation:** 20% in 3rd decade โ†’ 75% in 7th decade - **Gender Difference:** Women have larger, more numerous cysts - **Estrogen Effect:** Pregnancy and HRT increase cyst growth - **Symptoms:** Abdominal pain, early satiety, GERD - **Severe Disease:** May require intervention or transplant ### ๐Ÿฆด Other Extrarenal Manifestations - **Colonic Diverticulosis:** Increased risk vs general population - **Pancreatic Cysts:** ~9% of patients \>20 years - **Cardiac Valves:** Mitral valve prolapse more common - **Thoracic Aortic Aneurysms:** Elevated risk reported - **Abdominal Aortic:** No increased risk - **Hernia:** Inguinal and umbilical hernias common ### ๐Ÿฅ Comprehensive ADPKD Management Strategy 1 **Blood Pressure Control:** ACE-I/ARB first-line, aggressive targets \<110/75 mmHg in young patients with preserved function 2 **Water Intake:** Target 3-4L daily to suppress vasopressin (limited evidence but low risk intervention) 3 **Screening Programs:** MRA (not MRI) for aneurysms, family screening protocols 4 **Disease Monitoring:** MRI for TKV measurement (superior to volumetric CT), eGFR tracking 5 **Tolvaptan Evaluation:** CKD stages 1-4 (eGFR โ‰ฅ25) with rapid progression, monthly LFTs ร— 18 months 6 **Transplant Planning:** Refer at eGFR 20-25 mL/min/1.73mยฒ, usually unilateral nephrectomy ### ๐Ÿ“ท Best Imaging Modalities for ADPKD #### ๐Ÿงฒ MRI for Total Kidney Volume - **Superior to CT:** More accurate TKV measurements - **No Radiation:** Safe for repeated monitoring - **Better Contrast:** Superior soft tissue contrast - **Gold Standard:** For Tolvaptan eligibility assessment #### ๐Ÿง  MRA for Aneurysm Screening - **Test of Choice:** NOT standard brain MRI - **Vessel Imaging:** Specifically visualizes cerebral vasculature - **Detection Limit:** Can identify aneurysms โ‰ฅ3mm - **No Contrast:** Time-of-flight technique preferred #### ๐Ÿ” Ultrasound for Diagnosis - **Initial Screening:** First-line diagnostic tool - **Age-Specific Criteria:** Pei-Ravine criteria application - **Limitations:** Cannot accurately measure TKV - **Family Screening:** Cost-effective for relatives ### ๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘งโ€๐Ÿ‘ฆ Family Screening Protocols #### Age 15-39 Years - **Diagnostic Threshold:** โ‰ฅ3 cysts total (unilateral or bilateral) indicates ADPKD - **Special Consideration:** Ages 15-19, even 1-2 cysts may be significant - **Genetic Testing:** Consider for family planning purposes - **Repeat if Negative:** Every 3-5 years until age 30 #### Age 40+ Years - **Exclusion Rule:** โ‰ค2 cysts rules out ADPKD (high NPV) - **Diagnostic Threshold:** โ‰ฅ3 cysts per kidney for ages 40-59 - **Age 60+:** โ‰ฅ4 cysts per kidney required - **Late Negative:** Very unlikely to develop ADPKD after 30 #### Follow-up Protocols - **Initial Negative (Age 15):** Repeat at age 18 - **Ages 18-30:** Every 3-5 years if negative - **After Age 30:** If consistently negative, ADPKD very unlikely - **Genetic Counseling:** Important for all family members ### ๐Ÿซ€ Transplant Planning & Surgical Considerations #### โฐ Transplant Timing - **Referral Timing:** eGFR approaches 20-25 mL/min/1.73mยฒ - **Early Planning:** Allows time for workup and living donor identification - **Current Function:** eGFR 78 - too early for formal evaluation - **Patient Education:** Appropriate to begin discussions #### โš”๏ธ Nephrectomy Considerations - **Usually Unilateral:** Single kidney removal to create space - **Bilateral Rare:** Carries significant risk of severe hypotension - **Immediate Risk:** Bilateral requires immediate transplantation - **Indications:** Mass effect, recurrent infections, space constraints #### ๐ŸŽฏ ADPKD-Specific Factors - **Unique Consideration:** Large kidneys may need removal - **Good Outcomes:** Similar to other kidney diseases - **Living Donors:** Can receive from relatives (if unaffected) - **Space Planning:** Surgical approach differs from other causes ### ๐ŸŽฏ Key Clinical Pearls #### Disease Modification Tolvaptan is first approved therapy that slows kidney function decline in high-risk patients with adequate monitoring. #### TKV Predicts Progression Height-adjusted total kidney volume is the most important predictor of future renal function decline and ESRD. #### Systemic Disease ADPKD affects multiple organs requiring comprehensive screening for intracranial aneurysms and liver involvement. #### Genetic Counseling PKD1 vs PKD2 mutations significantly affect disease severity and progression timeline, informing patient counseling. --- [Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/kidney-cysts-masses/cystic-diseases/adpkd.html) ยท Markdown synchronized October 3, 2026.